# An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma

> **NCT02576509** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 743 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT02576509
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-07
- **Primary completion:** 2019-05-30
- **Final completion:** 2024-02-07
- **Target enrollment:** 743 (ACTUAL)
- **Last updated:** 2025-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02576509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02576509, "An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02576509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*